| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5687437 | The Journal of Urology | 2017 | 6 Pages |
Abstract
Among patients undergoing cytoreductive nephrectomy for metastatic renal cell carcinoma, lymph node dissection was not associated with improved oncologic outcomes in the overall cohort, for patients with preoperative radiographic lymphadenopathy or across increasing probability thresholds for pN1 disease. These findings suggest that lymph node dissection at cytoreductive nephrectomy does not confer an oncologic benefit by cytoreduction of nodal metastases. The presence of nodal metastases is associated with more aggressive tumor biology.
Keywords
ACMCSSIPWCytoreduction surgical proceduresRCCCSMLNDLymph node excisionCancer specific survivalLymph node dissectioncomputerized tomographyRenal cellbody mass indexBMINeoplasm metastasisCancer specific mortalityCytoreductive nephrectomyNephrectomyPropensity scoreAll cause mortalityRenal cell carcinomaCarcinoma
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Boris Gershman, R. Houston Thompson, Daniel M. Moreira, Stephen A. Boorjian, Christine M. Lohse, Brian A. Costello, John C. Cheville, Bradley C. Leibovich,